Vaults play no direct role in the multiple drug resistance phenotype in non-small cell lung carcinoma cells; their cellular function remains unknown.

Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.

mRNA expression predicts chemotherapy response and survival in patients with non-small cell lung cancer who received neoadjuvant cisplatin-based chemotherapy

Loss of p53-related suppression of lung resistance-related protein through Y-box binding protein 1 may be the reason for LRP expression increase, and, therefore, chemotherapy resistance in tumor cells.

LRP and MRP play a role in multidrug resistance in non-small cell lung cancer (NSCLC) and are related to prognosis in patients with NSCLC

lung resistance-related protein is associated with malignant ascitic cells and recurrence in ovarian serous carcinoma.

NSCLCs [ non-small cell lung cancer ] expressing P-gp [P-glycoprotein ]/LRP [ lung resistance-related protein] bear the EGFR [epidermal growth factor receptor] mutation in exon 19 or 21 easily.

Taxus chinensis var.-mediated downregulation of MRP1, MDR1, and LRP might contribute to the reversal of drug resistance in non-small cell lung cancer stem cells.

involved in doxorubicin resistance of non-small cell lung cancer

KIF4A promotes drug resistance of lung adenocarcinoma cells through transporting LRP-based vaults along microtubules towards the cell membrane

Study found that MVP expression was significantly up-regulated in non-small cell lung cancer (NSCLC) tissues. Higher MVP expression was correlated with better clinical outcomes in patients with lung cancer. Further findings demonstrate that MVP may act as a lung tumor suppressor via inhibiting STAT3 pathway.